Pentosan Polysulfate
PEPTIDES+ MEMBERS ONLY
INDICATIONS FOR USE
Pentosan Polysulfate (PPS) is used off-label and experimentally for its potential benefits in joint health, cartilage repair, and chronic inflammatory conditions. Originally FDA-approved for interstitial cystitis (oral formulation), PPS has gained interest in regenerative medicine—particularly in osteoarthritis and degenerative joint disease—due to its anti-inflammatory, anticoagulant, and disease-modifying properties.
ROUTE OF ADMINISTRATION
Subcutaneous Injection (off-label for joint and systemic use)
FORMULATIONS AND PRICING
| Formulation | Price |
|---|---|
| 250mg/mL MDV (5mL) | $90 |
COMMON INITIAL DOSING REGIMENS
Subcutaneous protocols typically involve 2 mg/kg injected twice weekly for 3–6 weeks, often followed by maintenance doses administered weekly or monthly.
MECHANISM OF ACTION
Pentosan Polysulfate is a semi-synthetic polysaccharide with structural similarities to glycosaminoglycans found in cartilage and connective tissue. It exhibits anti-inflammatory activity by inhibiting cytokines such as TNF-alpha and IL-1, reduces complement activation, and has mild anticoagulant properties.
In musculoskeletal applications, PPS may stimulate cartilage matrix production, improve synovial fluid viscosity, and decrease joint degeneration. It has been shown in veterinary use (particularly in equine and canine osteoarthritis) to enhance mobility and reduce pain.
COMMON SIDE EFFECTS
General: Headache, fatigue, or dizziness.
Gastrointestinal: Nausea, diarrhea, or abdominal discomfort.
Dermatologic: Bruising or delayed healing due to mild anticoagulant effects.
Injection Site: Mild redness, pain, or swelling.
Rare: Hematuria (blood in urine), elevated liver enzymes, or allergic reactions. Very rare reports of maculopathy with long-term high-dose oral use.
CONTRAINDICATIONS
Absolute: Known hypersensitivity to Pentosan Polysulfate. Active bleeding disorders or anticoagulant therapy.
Relative: Use with caution in patients with liver impairment, peptic ulcer disease, or upcoming surgical procedures. Regular monitoring may be necessary during prolonged treatment.
COMPARISON WITH OTHER AGENTS
Hyaluronic Acid Injections: These improve joint lubrication but do not offer disease-modifying properties. PPS may have broader regenerative effects by reducing inflammation and promoting cartilage repair.
NSAIDs: While NSAIDs provide symptom relief, PPS aims to address underlying joint degeneration and inflammation without GI or cardiovascular toxicity seen in chronic NSAID use.
Peptides (e.g., BPC-157, TB-500): These promote soft tissue healing and reduce inflammation. PPS may complement these agents in joint-specific protocols, with added benefits to cartilage and synovial structures.
EXPERIMENTAL TREATMENT DISCLAIMER:
Pentosan Polysulfate is FDA-approved only for oral use in the treatment of interstitial cystitis. All other uses—including injectable forms for musculoskeletal or regenerative applications—are considered experimental. Long-term safety data for off-label administration routes are limited. The patient acknowledges that this is an investigational therapy and accepts all associated risks.
MORE INFORMATION
FDA Safety Data Sheet not available (experimental peptide).